MedTrace Logo

Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis

NCT04507763 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 763

Last updated 2021-10-28

Study results available
· View outcomes & findings →

Summary

This study is to evaluate available data in Iraqi patients with ankylosing spondylitis on Enbrel treatment with regards to the impact of early treatment using data from the Baghdad Teaching Hospital registry

Conditions

Interventions

DRUG

Etanercept

Patients with ankylosing spondylitis as provided in real world practice

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2020-10-01
Completion
2020-10-01

Countries

  • Iraq

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04507763 on ClinicalTrials.gov